the ability of bone marrow (BM)-derived circulating EPCs to induce neovascularization. The obvious therapeutic potential of EPCs for ischemic diseases has since driven intense research focused on vasculogenic cells from diverse sources with variable phenotypic attributes and biological functions. Although data from clinical trials have shown a modest positive impact of circulating progenitor therapy in cardiovascular and peripheral arterial diseases, [3] [4] [5] [6] [7] new and enhanced methods for cell isolation, expansion, and characterization are critically important to improve regenerative outcomes. Indeed, the rarity of circulating EPCs remains a major hurdle toward successful and wider clinical application using autologous cells. The MNC fraction from PB contains primarily lineage-committed lymphoid and myeloid cells and a very small percentage of CD34 + or CD133 + stem/progenitor cells.
Accordingly, attempts have been made to mobilize EPCs into PB with repeated administration of granulocyte colony stimulating factor (G-CSF) followed by apheresis, a common practice in the setting of BM transplantation. Although several clinical trials of tissue regeneration have been completed with progenitors harvested from PB following G-CSF injection, successful expansion of EPCs from PB would be a preferable approach to circumvent the need for G-CSF therapy. Moreover, although BM harvest is a minimally invasive procedure, phlebotomy for PB is less expensive and tolerated better by patients. 8 Multimodality assessments showed increased perfusion, angiogenesis, and myogenesis and reduced fibrosis in QQMNC-treated mice. Important from a therapeutic standpoint, compared with G-CSF-mobilized CD34 + cell transplantation, QQMNC injection led to equal or greater improvement in outcomes in the setting of hindlimb ischemia. With growing clinical need for EPCs in large numbers, various methods of enrichment and expansion have been developed by different laboratories for EPCs with diverse cellular phenotypes. Consistent with an endothelial or angiogenic theme, the culture medium for this purpose usually contains an endothelial medium (eg, endothelial basal medium-2 9 and endothelial growth medium-2 10, 11 ) with or without serum and angiogenic growth factors. These factors usually include varying combinations and concentrations of vascular endothelial growth factor, fibroblast growth factor-B, insulin-like growth factor-1, epidermal growth factor, hydrocortisone, ascorbic acid, and heparin. 10, 12 Somewhat differently, the QQc medium used in this study by Masuda et al 8 contained Stemline â II (Sigma-Aldrich), a hematopoietic stem cell expansion medium, which did not contain any cytokine or
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serum. In addition to the angiogenic molecule vascular endothelial growth factor, the supplements in QQc medium included stem cell factor, thrombopoietin, IL-6, and Flt-3 ligand, molecules that are known to play important roles in the regulation of hematopoiesis and have been used extensively for expansion of cord blood-or peripheral blood-derived CD34 + cells. [13] [14] [15] While the molecular regulation of immune cells and inflammation in vivo is extremely complex, the ingredients of this QQc medium may potentially exert antiinflammatory and immune-tolerant actions by altering the T helper 1 (Th1)/Th2 cell balance. In this regard, IL-6 has been shown to promote the generation of the Th2 subset, 18 and human PBMNCs produce Th2 cytokines in response to vascular endothelial growth factor. 19 In humans, Flt-3 ligand increases both 
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